

# ETV6 mutations in early immature human T cell leukemias

Pieter Van Vlierberghe,<sup>1</sup> Alberto Ambesi-Impiombato,<sup>1</sup> Arianne Perez-Garcia,<sup>1</sup> J. Erika Haydu,<sup>1</sup> Isaura Rigo,<sup>1</sup> Michael Hadler,<sup>1</sup> Valeria Tosello,<sup>1</sup> Giusy Della Gatta,<sup>1</sup> Elisabeth Paietta,<sup>4</sup> Janis Racevskis,<sup>4</sup> Peter H. Wiernik,<sup>4</sup> Selina M. Luger,<sup>5</sup> Jacob M. Rowe,<sup>6</sup> Montserrat Rue,<sup>7</sup> and Adolfo A. Ferrando<sup>1,2,3</sup>

<sup>1</sup>Institute for Cancer Genetics, <sup>2</sup>Department of Pediatrics, and <sup>3</sup>Department of Pathology, Columbia University Medical Center, New York, NY 10032

<sup>4</sup>Montefiore Medical Center North, Bronx, New York, NY 10467

<sup>5</sup>Hematologic Malignancies and Stem Cell Transplant Program, Hematology-Oncology Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104

<sup>6</sup>Rambam Medical Center, Haifa 31096, Israel

<sup>7</sup>Department of Basic Medical Sciences, University of Lleida, Lleida 25003, Spain

Early immature T cell acute lymphoblastic leukemias (T-ALLs) account for ~5–10% of pediatric T-ALLs and are associated with poor prognosis. However, the genetic defects that drive the biology of these tumors remain largely unknown. In this study, analysis of microarray gene expression signatures in adult T-ALL demonstrated a high prevalence of early immature leukemias and revealed a close relationship between these tumors and myeloid leukemias. Many adult immature T-ALLs harbored mutations in myeloid-specific oncogenes and tumor suppressors including *IDH1*, *IDH2*, *DNMT3A*, *FLT3*, and *NRAS*. Moreover, we identified *ETV6* mutations as a novel genetic lesion uniquely present in immature adult T-ALL. Our results demonstrate that early immature adult T-ALL represents a heterogeneous category of leukemias characterized by the presence of overlapping myeloid and T-ALL characteristics, and highlight the potential role of *ETV6* mutations in these tumors.

## CORRESPONDENCE

Adolfo A. Ferrando:  
af2196@columbia.edu

Abbreviations used: AML, acute myeloid leukemia; ETP, early T cell precursor; GSEA, gene set enrichment analysis; siRNA, small interfering RNA; T-ALL, T cell acute lymphoblastic leukemia.

T cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous disease in which genetic lesions coordinately affect cell proliferation, differentiation, and survival of thymocytes (Ferrando, 2009; Paganin and Ferrando, 2011). T-ALL accounts for 15% of pediatric and 25% of adult ALL cases. Importantly, significant differences in outcome are present between pediatric and adult T-ALL (Pui et al., 2008). Thus, although >70% of children achieve long lasting complete remissions, only 50% of adult T-ALL patients are currently cured. In addition, pediatric and adult T-ALLs show marked differences in the frequency of specific genetic lesions. For example, chromosomal translocation and aberrant expression of the *TAL1* and *TLX3* oncogenes are highly prevalent in children, but rare in adults. In contrast, translocations activating *TLX1* are rarely

found in pediatric leukemias but represent one third of adult T-ALL cases (Ferrando et al., 2002, 2004).


## RESULTS AND DISCUSSION

To gain more insight in the genetic and oncogenic mechanisms driving adult T-ALL, we analyzed a series of 57 T-ALL samples treated in the Eastern Cooperative Oncology Group (ECOG) E2993 protocol (Marks et al., 2009) using gene expression oligonucleotide microarrays. Unsupervised analysis and consensus clustering of microarray gene expression data revealed the presence of 2 stable gene expression clusters (Cluster I and II) encompassing approximately half of the tumor samples analyzed each (Fig. 1 A). Supervised analysis demonstrated that each of these two groups

© 2011 Van Vlierberghe et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

P. Van Vlierberghe and A. Ambesi-Impiombato contributed equally to this paper.

Supplemental Material can be found at:  
<http://jem.rupress.org/content/suppl/2011/12/15/jem.20112239.DC1.html>



**Figure 1. Gene expression profiling identifies high prevalence of early immature leukemias in adult T-ALL.** (A) Consensus clustering of microarray gene expression data of 57 adult T-ALL samples. (B) Top 50 differentially expressed genes between adult T-ALL cluster I and cluster II samples. Genes in the heat map are shown in rows and each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units with red indicating higher levels and blue lower levels of expression. (C) GSEA analysis of early immature/*LYL1*-positive, early cortical/*TLX1*-positive, and late cortical/*TAL1*-positive associated genes in the gene expression clusters I and II identified in adult T-ALL. (D) GSEA of genes associated with pediatric ETP-T-ALLs in adult T-ALL gene expression clusters.

is characterized by a distinct gene expression program encompassing 365 differentially expressed unique genes (fold change  $>1.5$ ;  $P < 0.0001$ ; Fig. 1 B). Similar results were obtained in an independent validation set of 30 adult T-ALLs (Chiaretti et al., 2004). Thus, consensus clustering identified two robust clusters encompassing 12 and 18 samples, respectively in this series (Fig. S1). Moreover, cross analysis of clusters identified in the discovery and validation datasets using gene set enrichment analysis (GSEA) demonstrated a high level of enrichment in the expression signatures associated with clusters I and II in our discovery series in the clusters identified in this second dataset and vice versa, a high level of enrichment of a high level of enrichment in differentially expressed genes between clusters I and II in our validation series in the clusters identified in this our original dataset (Fig. S1).

Gene expression profiling of pediatric T-ALLs has defined distinct molecular subgroups associated with the activation of specific transcription factor oncogenes and unique gene expression signatures reflecting a distinct arrest during T cell development (Ferrando et al., 2002, 2004; Soulier et al., 2005; Homminga et al., 2011). Early immature/*LYL1*-positive T-ALLs show an early block at the double-negative

stage of thymocyte development (Ferrando et al., 2002). In contrast, early cortical T-ALLs are characteristically CD1a, CD4, and CD8 positive and are frequently associated with translocations inducing aberrant expression of the *TLX1* and *TLX3* homeobox transcription factor oncogenes (Ferrando et al., 2002). Finally, late cortical thymocyte T-ALLs show expression of CD4, CD8, and CD3 and activation of the *TAL1* transcription factor oncogene (Ferrando et al., 2002; Soulier et al., 2005; Homminga et al., 2011). GSEA of genes associated with these pediatric molecular groups of T-ALL (Ferrando et al., 2002) against the two clusters of adult T-ALLs identified in our series showed a highly significant enrichment of *LYL1*/immature T-ALL-associated genes in cluster I, whereas cluster II was associated with *TLX1*/early cortical and *TAL1*/late cortical T-ALL signatures (Fig. 1 C). Consistently, all *TLX1* ( $n = 5$ ) and *TLX3* ( $n = 5$ ), and 8/10 *TAL1* high/*LMO1*/*LMO2*, expression leukemias in this series were included in cluster II.


Notably, transcriptionally defined early immature adult T-ALLs in cluster I showed an early arrest in T cell development and were characterized by the expression of cytoplasmic CD3 together with early hematopoietic markers such as CD34 (22/29, 76%) and CD133 (14/29, 48%) and myeloid-associated antigens such as CD13 (19/29, 65%), CD33 (16/29, 55%), and CD11b (16/29, 55%; Table S1). However, despite these common features, we could still identify three different immunophenotype categories within this group based on the expression of CD5. Thus, 10/29 cases (34%) showed complete absence of surface CD5 expression, 16/29 (55%) showed low levels of surface CD5 expression, and 3/29 (11%) were strongly CD5 positive (Table S1).

Importantly, weak expression of CD5 in immature pediatric T-ALL leukemias has recently been associated with a gene expression program resembling early T cell progenitors and defines a group of childhood T-ALLs with poor prognosis (Coustan-Smith et al., 2009). To test the relationship of adult T-ALLs with early T cell precursor (ETP) pediatric T-ALLs, we performed GSEA of adult T-ALL clusters I and II using a gene set of ETP-T-ALL-associated transcripts (Coustan-Smith et al., 2009). This analysis showed a high level of enrichment of transcripts associated with this poor prognostic pediatric T-ALL group in adult immature/cluster I T-ALLs (Fig. 1 D).


To explore the relationship between the genetic program associated with adult early immature T-ALLs and normal thymocytes, we performed GSEA analysis of gene expression signatures associated with distinct human thymocyte subsets including early double-negative ( $CD34^+$ ,  $CD1a^-$ ,  $CD4^-$ ,  $CD8^-$ ), late double-negative ( $CD34^+$ ,  $CD1a^+$ ,  $CD4^-$ ,  $CD8^-$ ), immature single-positive ( $CD4^+$ ,  $CD8^-$ ,  $CD3^-$ ), early double-positive ( $CD4^+$ ,  $CD8^+$ ,  $CD3^-$ ), late double-positive ( $CD4^+$ ,  $CD8^+$ ,  $CD3^+$ ), mature CD4 single-positive ( $CD4^+$ ,  $CD8^-$ ,  $CD3^+$ ), and mature CD8 single-positive ( $CD4^-$ ,  $CD8^+$ ,  $CD3^+$ ) cells. This analysis demonstrated a significant enrichment of genes characteristic for the earliest double-negative ( $CD34^+$ ,  $CD1a^-$ ,  $CD4^-$ ,  $CD8^-$ ) T cell progenitors in the early immature T-ALL group (Fig. 2 A). Notably, early double-negative thymocytes are not yet committed to T cell development and retain multilineage potential (Bhandoola and Sambandam, 2006). Therefore, we

used a similar approach to analyze the relationship of early immature T-ALLs with other hematopoietic lineages and progenitor populations (Novershtern et al., 2011). Surprisingly, this analysis revealed a significant enrichment of genes up-regulated in long-term hematopoietic stem cells (Fig. 2 B) and in granulocyte-monocyte progenitors (Fig. 2 C) in this group. These results, together with the high prevalence of expression of immature ( $CD34$ ,  $CD133$ ) and myeloid ( $CD13$ ,  $CD33$ , and  $CD11b$ ) surface markers in these leukemias (Table S1) made us consider the possibility that early immature adult T-ALL tumors may be transcriptionally and genetically related to acute myeloid leukemias (AMLs).

To test this hypothesis, we analyzed the enrichment of lymphoid and myeloid leukemia gene expression signatures (Golub et al., 1999) in immature adult T-ALLs. This analysis revealed a highly significant enrichment of AML-associated transcripts in the early immature T-ALL cluster I group, whereas ALL associated transcripts were enriched in the T-ALL cluster II samples (Fig. 2, D and E). Based on this observation, we hypothesized that myeloid-specific genetic alterations might be uniquely present in immature adult T-ALLs. Strikingly, mutation analysis of AML oncogenes and tumor suppressor genes revealed the presence of myeloid mutations targeting *IDH1*, *IDH2*, *DNMT3A*, *FLT3*, and *NRAS* in 14/29 (48%) of immature adult T-ALL cases, whereas only 1/28 (3.5%) of all other adult T-ALLs showed a mutation in *NRAS* ( $P = 0.0001$ ; Fig. 2 F and Table S2). In addition, immature adult T-ALL samples showed a lower



**Figure 2. Myeloid and stem cell features of immature adult T-ALL.** (A–C) GSEA of transcripts significantly up-regulated in early immature adult T-ALL in gene expression signatures obtained from human early double negative thymocytes ( $CD34^+$  $CD1a^-$  $CD4^-$  $CD8^-$ ; A) against all other thymocyte groups, long term hematopoietic stem cells (LT-HSC; B), and granulocyte-monocyte progenitors (GMP; C) against all other hematopoietic populations. (D and E) GSEA of AML- (D) or ALL-associated (E) transcripts in early immature (cluster I) versus other (cluster II) adult T-ALLs. (F) Differential distribution of myeloid-specific lesions in immature (cluster I) versus other (cluster II) adult T-ALLs.



**Figure 3. ETV6 mutations in early immature adult T-ALL.** (A) Schematic representation of the structure of the ETV6 protein. The N-terminal pointed (PNT) homodimerization domain and the C-terminal DNA-binding domain (ETS-domain) are indicated. ETV6 mutations identified in primary adult T-ALL samples are shown. Filled circles represent frameshift mutations, whereas the splice acceptor mutation in the exon 8 splice acceptor sequence is depicted as an open circle. (B and C) Representative DNA sequencing chromatograms of paired diagnosis and remission genomic T-ALL DNA samples showing a somatic frameshift mutation in exon 6 (B) and a splice acceptor mutation in exon 8 of ETV6 (C). (D) Sequence analysis of paired ETV6 genomic DNA and cDNA shows biallelic expression of wild-type and mutant ETV6 transcripts.

prevalence of prototypical T-ALL genetic alterations such as activating mutations in the *IL7R* gene (1/29 [3.5%] immature adult T-ALLs vs. 6/28 [21.5%] of all other adult T-ALL samples;  $P < 0.05$ ) and mutations in *NOTCH1* and *FBXW7* activating the NOTCH-signaling pathway (12/29 [41%] immature adult T-ALLs vs. 26/28 [93%] of all other adult T-ALLs;  $P < 0.05$ ; Table S2). Notably, myeloid-specific gene alterations and mutations activating *IL7R* or NOTCH signaling were overlapping in 7/29 (24%) of all immature adult T-ALLs (Table S2). Overall, these results show that early immature adult T-ALLs are a gray zone leukemia category characterized by the

**Table 1. ETV6 mutations in early immature adult T-ALL**

Sample ID	Exon	ETV6 mutations			T-ALL specific lesions Myeloid specific lesions				
		Predicted amino acid change	Homozygous/heterozygous	Somatic/germline	NOTCH1	FBXW7	NRAS	IDH2	DNMT3A
3	3	S105fs	het	NA	MUT	WT	MUT	WT	WT
5	8	R417fs	het	somatic	MUT	WT	WT	WT	WT
18	3	Y103fs	homo (LOH)	somatic	MUT	WT	WT	WT	WT
24	4	S130fs	het	somatic	MUT	WT	WT	WT	WT
27	2	P50fs	het	NA	MUT	WT	MUT	WT	WT
58	5	L178fs	het	NA	WT	WT	WT	MUT	MUT
59	5	V158fs	het	NA	MUT	WT	WT	WT	MUT
60	3	V66fs	het	NA	WT	WT	WT	WT	WT
61	6	V345fs	het	somatic	MUT	WT	WT	WT	WT
62	6	N356fs	homo (LOH)	NA	MUT	WT	WT	WT	WT


LOH, loss of heterozygosity; NA, not available



presence of overlapping myeloid and T-lymphoid immunophenotypic features and genetic alterations.

Notably, a similar cooccurrence of both T lymphoid and myeloid characteristics has been previously documented in rare leukemias harboring the translocation t(8;12)(q13;p13), which results in the fusion of the *ETV6* tumor suppressor and the *NCOA2* gene (Strehl et al., 2008; Homminga et al., 2011). Given the prominent role of *ETV6* in hematopoietic stem cell homeostasis (Hock et al., 2004) and to test a possible

broader role of *ETV6* in the pathogenesis of T-ALL, we screened all coding exons of *ETV6* for the presence of somatic mutations in an extended series of adult leukemia cases. This analysis revealed the presence of *ETV6* mutations in 10 out of 82 (12%) adult T-ALL samples analyzed (Fig. 3, A–C; Table 1). Strikingly, *ETV6* mutations were exclusively found in early immature adult T-ALLs with expression of the early hematopoietic marker CD34, cytoplasmic CD3, and the myeloid-associated antigen CD33 in the absence of CD4 and CD8 (Table S3). The overall incidence of *ETV6* mutations in immature adult T-ALL in this series was 10 out of 41 (24%). In seven cases, *ETV6* mutations corresponded to frameshift insertions or deletions in the N-terminal part of the protein, whereas the three remaining alleles corresponded to C-terminal truncating alleles (2 frameshift insertions and deletions and an exon 8 splice acceptor site mutation; Fig. 3 A). Analysis of bone marrow remission genomic DNA confirmed the somatic origin of *ETV6* mutations (three frameshift and one splice site) in each of the four patient samples with available material (Fig. 3, B and C; Table 1). *ETV6* mutations found in T-ALL were heterozygous in 8 out of




**Figure 4. Functional analysis of truncating *ETV6* mutant alleles.** (A and B) Western blot analysis of FLAG-tagged N-terminal (Y103fs, S105fs) (A) and C-terminal (V345fs, N356fs) (B) *ETV6* mutants expressed in HEK293T cells. The FLAG epitope was introduced in the C terminus of the N-terminal Y103fs and S105fs mutants and in the N terminus of the C-terminal *ETV6* V345fs and N356fs mutants. Blots were probed with anti-FLAG or anti-GAPDH as loading control. (C) Lysates from primary adult T-ALL samples harboring a heterozygous C-terminal (V345fs, #61) and a homozygous N-terminal (Y103fs, #18) *ETV6* mutation were analyzed by Western blot. Wild-type *ETV6* proteins are detected as 50 and 57 kD anti-*ETV6* immunoreactive bands and anti-GAPDH as loading control. (D) Effects of *ETV6* mutant alleles in the activity of an *ETV6*-responsive reporter plasmid (pGL2-754TR). Luciferase activity is shown relative to empty vector and normalized using an internal control plasmid expressing Renilla luciferase. Experiments were performed in triplicate and repeated at least twice. (E) Luciferase assay analyzing the effects of increasing amounts (indicated by wedges) of C-terminal (V345fs) and N-terminal (S105fs) *ETV6* mutants on the activity of wild-type *ETV6*. Experiments were performed in triplicate and repeated at least twice. (F) Supervised analysis of *ETV6* mutant versus wild-type gene expression signatures in early immature adult T-ALLs ( $P < 0.001$ ). Top 50 differentially expressed genes are shown. Genes in the heat map are shown in rows, each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.

10 cases (80%) with two patient samples showing copy neutral loss of heterozygosity resulting in homozygous N-terminal and C-terminal truncating alleles (Table 1). RT-PCR analysis confirmed expression of the remaining wild-type *ETV6* allele in heterozygous *ETV6* mutant adult T-ALL samples (Fig. 3 D). In addition, and in contrast with the lower incidence of *NOTCH1* mutations present in the immature group, 8/10 (80%) of *ETV6* mutant T-ALL cases showed mutations in *NOTCH1* (Table 1), suggesting a specific interaction between the oncogenic programs activated by *NOTCH1* and mutational loss of *ETV6* in the pathogenesis of adult immature T cell lymphoblastic leukemia.

The *ETV6* tumor suppressor gene is frequently translocated in lymphoid and myeloid hematopoietic tumors and encodes a transcriptional repressor with an N-terminal pointed (PNT) homodimerization domain and a C-terminal ETS DNA-binding domain (Bohlander, 2005). Transfection of plasmids driving the expression of N-terminal truncating *ETV6* mutations (Y103fs, S105fs) found in adult T-ALL resulted in the activation of the M208 and M240 internal translation initiation sites (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2005) and the expression of N-terminal truncated protein products (23 and 28 kD) devoid of the

PNT domain and retaining the DNA-binding domain (Fig. 4 A). C-terminal *ETV6* truncating mutations (V345fs, N356fs) resulted in the expression of C-terminal truncated polypeptides (42 and 44 kD, respectively; Fig. 4 B). Consistently, Western blot analysis of a primary patient sample harboring a homozygous N-terminal truncating mutation detected the presence of shorter mutant *ETV6* isoforms (23 and 28 kD; Fig. 4 C), whereas analysis of a sample with a heterozygous C-terminal mutation revealed the expression of both wild-type (50 and 57 kD) and truncated (42 kD) *ETV6* proteins (Fig. 4 C).

To elucidate the functional consequences of *ETV6* alterations, we performed luciferase reporter assays using an *ETV6*-responsive reporter construct (pGL2-754TR) derived from the stromelysin-1 gene (Fenrick et al., 2000). In line with the role of *ETV6* as transcriptional repressor, expression of wild-type *ETV6* strongly decreased luciferase activity (Fig. 4 D). In contrast, C-terminal (V345fs; N356fs) and N-terminal (Y103fs; S105fs) *ETV6* mutants were functionally inactive with no transcriptional repression activity (Fig. 4 D). Moreover, expression of C-terminal (V345fs) and N-terminal (S105fs) *ETV6* mutants abolished the transrepression effects of wild-type *ETV6* (Fig. 4 E), suggesting that



**Figure 5. Transcriptional program regulated by *ETV6* in T-ALL.** (A) RT-PCR (top) and Western blot (bottom) analysis of *ETV6* expression in LOUCY cells expressing control siRNA or one of two *ETV6*-specific siRNAs. (B) GSEA of the early immature *ETV6* mutant T-ALL-associated transcripts in control siRNA versus *ETV6* knockdown LOUCY cells. Heatmap of genes up-regulated in early immature *ETV6* mutant T-ALL most differentially expressed in control siRNA versus *ETV6* knockdown LOUCY cells. The myeloid marker *CD33* and genes involved in leukemia development and stem cell homeostasis are shown in red. Genes in the heat map are shown in rows and each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.

these mutant *ETV6* alleles harbor dominant-negative activity. Consistently, supervised analysis of microarray gene expression signatures of *ETV6* wild-type ( $n = 19$ ) and *ETV6*-mutated ( $n = 9$ ) immature adult T cell leukemias showed that *ETV6*-mutated cases have a characteristic gene expression signature dominated by up-regulated transcripts (Fig. 4 F and Fig. S2), which included the myeloid marker *CD33* and genes involved in leukemia development and stem cell homeostasis, such as *HOXA13* (Su et al., 2006; Bach et al., 2010), *TP63* (Bernassola et al., 2005; Crum and McKeon, 2010), *PTEN* (Yilmaz et al., 2006; Zhang et al., 2006), and *PRDM16* (Du et al., 2005; Chuikov et al., 2010), which is a gene translocated to the *ETV6* locus in AML (Duhoux et al., 2011; Fig. 4 F). Notably, all *ETV6* mutant T-ALL samples in our series were characteristically CD33 positive (5/5 [100%] immature *ETV6* mutant T-ALLs vs. 11/24 [46%] immature *ETV6* wild-type T-ALLs;  $P < 0.05$ ; Table S3).

After these results, and to test the transcriptional effects of *ETV6* inactivation in immature T-ALL, we analyzed the gene expression changes induced upon small interfering RNA (siRNA)-mediated knockdown of *ETV6* in LOUCY cells, a T-ALL cell line with a transcriptional program highly related to that of immature T-ALLs (Fig. 5 A, Fig. S3). Notably, GSEA analysis of this *ETV6* knockdown signature showed a significant enrichment in genes that are characteristically up-regulated in *ETV6* mutant immature T-ALLs, including *HOXA13*, *PRDM16*, *PTEN*, and *CD33* ( $P = 0.016$ ; Fig. 5 B).

Overall, our results demonstrate a high prevalence of early immature T-ALLs in adult T-ALL, which show increased heterogeneity in their immunophenotypes compared with pediatric ETP-TALLs, mixed lymphoid and myeloid characteristics, and frequent truncating mutations in the *ETV6* tumor suppressor gene.

## MATERIALS AND METHODS

**Patient samples and cell lines.** Leukemic DNA and cryopreserved lymphoblast samples were provided by the Eastern Cooperative Oncology Group (ECOG). All samples were collected in clinical trials E2993 (Marks et al., 2009) and C10403. Informed consent to use leftover material for research purposes was obtained from all the patients at trial entry according to the Declaration of Helsinki. T cell phenotype was confirmed by flow cytometry. In total, 82 adult T-ALL samples were used in this study, including 57 samples used for the gene expression profiling study and mutation analysis and 25 additional cases used for mutation screening.

The LOUCY cell line was cultured in RPMI-1640 media supplemented with 10% fetal bovine serum, 100 U/ml penicillin G, and 100  $\mu$ g/ml streptomycin at 37°C in a humidified atmosphere under 5% CO<sub>2</sub>. HEK293T cells were cultured under similar conditions in DME media.

### Sorting of human thymocyte populations from human thymus.

Thymus samples were obtained as surgical tissue discards from 3 pediatric patients (age from 7 d to 6 mo) undergoing cardiac surgery at the New York Presbyterian Hospital. Single-cell suspensions were prepared by dissecting the thymus into small pieces and passing the tissue through a cell strainer (diameter 70  $\mu$ m), and mononuclear cells were isolated by Ficoll density centrifugation (GE Healthcare). CD34<sup>+</sup> human thymocyte populations were obtained by positive selection using magnetically activated cell sorting using the CD34 MicroBead kit (Miltenyi Biotec) and by negative selection using the CD3 MicroBead kit (Miltenyi Biotec). Magnetically isolated CD34<sup>+</sup> cells

were then labeled with fluorophore-conjugated monoclonal antibodies against CD34 (CD34-APC) and CD1a (CD1-PE; BD). Early double negative thymocytes (CD34<sup>+</sup>CD1a<sup>−</sup>CD3<sup>−</sup>CD4<sup>−</sup>CD8<sup>−</sup>) and late double negative thymocytes (CD34<sup>+</sup>CD1a<sup>+</sup>CD3<sup>−</sup>CD4<sup>−</sup>CD8<sup>−</sup>) were isolated by FACS. Immature single-positive thymocytes (CD4<sup>+</sup>CD8<sup>−</sup>CD3<sup>−</sup>), were isolated by FACS after immunomagnetic depletion of total thymocytes with the CD3 MicroBead kit (Miltenyi Biotec) and immunostaining with CD4-PE (BD) and CD34-FITC antibodies. Early double-positive cells (CD4<sup>+</sup>CD8<sup>+</sup>CD3<sup>−</sup>) were isolated by FACS from CD3 immunodepleted cells after staining with CD4-PE and CD8-FITC (BD) antibodies. Late double-positive (CD4<sup>+</sup>CD8<sup>+</sup>CD3<sup>+</sup>) and mature single-positive CD4 (CD4<sup>+</sup>CD3<sup>+</sup>) and CD8 (CD8<sup>+</sup>CD3<sup>+</sup>) thymocytes were FACS after triple immunolabeling with CD4-PE, CD8-FITC, and CD3-APC (BD) antibodies. Cell sorting was performed with a FACSDiva cell sorter (BD), and the purity of all sorted populations was >95%.

### Microarray gene expression profiling of normal T cell subsets and primary adult T-ALL samples.

RNA isolation from sorted subsets of human thymocytes was performed in triplicate using the RNeasy Micro kit (QIAGEN) according to manufacturer's protocol. Next, 10 ng of RNA from each T cell subset was amplified using the Ovation PicoSL WTA System (NuGen), labeled by the Encore BiotinIL Module (NuGen), and hybridized to the HumanHT-12 v4 Expression BeadChip (Illumina) according to manufacturer's protocol. Similarly, RNA isolation from lymphoblast obtained from adult T-ALL patient samples was achieved using the RNeasy plus mini kit (QIAGEN) according to manufacturer's protocol. Next, 500 ng of RNA was amplified and biotinylated using the TotalPrep RNA Amplification kit (Invitrogen) and hybridized to the HumanHT-12 v4 Expression BeadChip (Illumina).

Gene expression profiling data from 57 adult T-ALL patients and normal T cell subsets were normalized using quantile normalization without background subtraction. Unsupervised consensus clustering was performed with  $K = 2$ , as previously described (Monti et al., 2003), using the GenePattern application (Gould et al., 2006). Genes differentially expressed between cluster I and cluster II adult T-ALL cases were identified using the Comparative Marker Selection application in GenePattern (Gould et al., 2006) using a nonparametric  $P$  value calculation with 1,000 permutations.

A validation series of 30 previously reported adult T-ALL microarray data (Chiaretti et al., 2004) was normalized with GC-RMA using the open-source Bioconductor project ([www.bioconductor.org](http://www.bioconductor.org)) within the statistical programming language R (<http://cran.r-project.org/>). In this series, we selected the top 250 most variable probes from the unsupervised consensus clustering analysis of the 57 ECOG T-ALL expression samples in our discovery series matched by gene names for consensus clustering as described in the previous paragraph. The relationship of clusters identified in the discovery series and validation series was established by cross GSEA analysis (Subramanian et al., 2005) of the top up- and down-regulated genes (Student's  $t$  test,  $P < 0.0001$ ) in clusters I and cluster II of one series against the list of genes ranked by the  $t$ -score (cluster I vs. cluster II) in the other.

Enrichment of early immature/*LYL1*-positive, early cortical/*TLX1*, and late cortical/*TAL1*-associated genes in the gene expression clusters identified in our adult T-ALL series was analyzed by GSEA using the  $t$  test metric and 1,000 permutations of the genes. In addition, enrichment of myeloid- and lymphoid-associated genes was studied by a similar GSEA analysis using myeloid and lymphoid (Golub et al., 1999) gene sets. Similarly, we analyzed the relationship of the early immature adult T-ALL signature with that of different sorted human hematopoietic populations (Novershtern et al., 2011; Gene Expression Omnibus [GEO] accession no. GSE24759), the gene expression profiles generated for the specific populations of sorted human thymocytes, and gene sets associated with ETP T-ALL (Coustan-Smith et al., 2009), as described above. GEO accession nos. for adult T-ALL and normal thymocyte microarray data analyzed here are GSE33469 and GSE33470, respectively.

Microarray data from human T-ALL cell lines (Palomero et al., 2007; GEO accession no. GSE5682) were analyzed for their relationship with



cluster I (early immature) and cluster II T-ALL signatures by GSEA using the Student's *t* test metric and 1,000 permutations of the genes.

**Sequence analysis.** All exon sequences from *ETV6* were amplified from genomic DNA by PCR and analyzed by direct dideoxynucleotide sequencing. Mutational hotspot regions for *FLT3*, *DNMT3A*, *IDH1*, *IDH2*, *NOTCH1*, *IL7R*, and *FBXW7* were sequenced. Primer sequences used for *FLT3* (Van Vlierberghe et al., 2005), *DNMT3A* (Ley et al., 2010), *IDH1* (Andersson et al., 2011), *IDH2* (Andersson et al., 2011), *NOTCH1* (Weng et al., 2004), *IL7R* (Zenatti et al., 2011), and *FBXW7* (Thompson et al., 2007) have been previously described. Primer sequences used for *ETV6* sequencing are shown in Table S4.

**Luciferase reporter assays.** We generated N-terminal or C-terminal FLAG-tagged wild-type and mutant *ETV6* constructs in the pCDNA3.1 (-) plasmid by direct PCR cloning from cDNA obtained from primary *ETV6* wild-type and mutant adult T-ALL samples. A FLAG epitope was introduced into the N terminus of the C-terminal *ETV6* V345fs and N356fs mutants and in the C terminus of the N-terminal Y103fs and S105fs mutants. We tested the *ETV6* transcriptional repression activity in a luciferase reporter assay using the pGL2-T574 reporter construct (Fenrick et al., 2000). In these assays, we transfected HEK293T cells with 50 ng of wild-type pCDNA3-*ETV6* or different types of N-terminal and C-terminal *ETV6* mutants, together with a plasmid driving the expression of the Renilla luciferase gene (pCMV-Renilla) used as transfection control. Alternatively, we transfected HEK293T cells with a constant amount of wild-type pCDNA3-*ETV6* in combination with increased concentrations of N-terminal and C-terminal *ETV6* mutant constructs at 1:1, 1:2, and 1:3 ratios. We measured luciferase activity 48 h after transfection with the Dual-Luciferase Reporter assay kit (Promega).

**Western blot.** Western blot analysis was performed using a mouse monoclonal antibody against *ETV6* (1:5,000; Abnova), a rabbit antibody against FLAG epitope (1:1,000; Cell Signaling Technology), and a mouse monoclonal antibody GAPDH (1:1,000; Santa Cruz Biotechnology, inc.) using standard procedures.

***ETV6* siRNA knockdown.** For siRNA-mediated knockdown of *ETV6* in the LOUCY T-ALL cell line, we performed electroporation of 50 nM *ETV6*-specific siRNAs (Applied Biosystems) or 50 nM of scramble siRNAs as control, using an exponential decay pulse (300 V, 1000  $\mu$ F; Genepulser MxCell, Bio-Rad). After 72 h, RNA was isolated using the RNeasy plus mini kit (QIAGEN) according to manufacturer's protocol. Knockdown of *ETV6* was evaluated by RT-PCR and Western blot analysis, after which the siRNA showing the highest *ETV6* knockdown (siRNA *ETV6*#1) was selected for further analysis. Finally, gene expression profiling of biological replicates for LOUCY siRNA scramble control and LOUCY siRNA *ETV6*#1 was performed using the HumanHT-12 v4 Expression BeadChip as described previously for the primary leukemia samples.

The GEO accession code for the microarray data of LOUCY cells upon siRNA *ETV6* knockdown analyzed here is GSE33820.

**Statistical analysis.** The Fisher's exact test was used to compare the frequency of specific genomic lesions between of immature and other adult T-ALL patients.

**Online supplemental material.** Fig. S1 shows a consensus clustering analysis of a validation series of 30 adult T-ALLs and cross GSEA analysis between clusters identified in the discovery and validation cohorts. Fig. S2 shows a heatmap of the supervised analysis from *ETV6* mutant versus *ETV6* wild-type gene expression signatures in early immature adult T-ALLs ( $P < 0.001$ ; FC  $> 1.25$ ). Fig. S3 shows GSEA analysis of transcripts significantly up-regulated in early immature adult T-ALL in gene expression signatures obtained from a panel of T-ALL cell lines. Table S1 shows an overview of the immunophenotypic features of the adult T-ALL samples

included in this study ( $n = 57$ ). Table S2 shows an overview of the myeloid and T-lymphoid specific genetic alterations in adult T-ALL. Table S3 shows the immunophenotypic features of the *ETV6* mutant adult T-ALL samples ( $n = 10$ ). Table S4 shows the primer sequences used for *ETV6* mutations analysis. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20112239/DC1>.

This study was supported by the Fund for Scientific Research Flanders (P. Van Vlierberghe); the ECOG tumor bank; the National Institutes of Health (R01CA120196 to A. F. and U24 CA114737 to E.P.); the Stand Up To Cancer Innovative Research Award (A.F.), the Chemotherapy Foundation (A.F.); the Rally Across America Foundation (A.F.); and the Swim Across America Foundation (A.F.). P. Van Vlierberghe is an ASH Scholar and A.F. is a Leukemia & Lymphoma Society Scholar.

The authors declare that they have no competing financial interests.

P. Van Vlierberghe performed experiments and wrote the manuscript. A.A. performed bioinformatic analyses including analysis of gene expression profiling data and GSEA. A.P. performed experiments. J.E.H. performed luciferase assays. I.R. isolated RNA and performed gene expression profiling of primary T-ALL samples. M.H. performed sequencing analysis of myeloid specific lesions. M.R. performed statistical analysis. E.P., J.R., P.H.W., S.M.L. and J.M.R. provided samples and correlative clinical and immunophenotypic data from ECOG. A.F. designed the studies, directed research and wrote the manuscript.

Submitted: 21 October 2011

Accepted: 30 November 2011


## REFERENCES

- Andersson, A.K., D.W. Miller, J.A. Lynch, A.S. Lemoff, Z. Cai, S.B. Pounds, I. Radtke, B. Yan, J.D. Schuetz, J.E. Rubnitz, et al. 2011. IDH1 and IDH2 mutations in pediatric acute leukemia. *Leukemia*. 25:1570–1577. <http://dx.doi.org/10.1038/leu.2011.133>
- Bach, C., S. Buhl, D. Mueller, M.P. García-Cuellar, E. Maethner, and R.K. Slany. 2010. Leukemogenic transformation by HOXA cluster genes. *Blood*. 115:2910–2918. <http://dx.doi.org/10.1182/blood-2009-04-216606>
- Barjesteh van Waalwijk van Doorn-Khosrovani, S., D. Spensberger, Y. de Knecht, M. Tang, B. Löwenberg, and R. Delwel. 2005. Somatic heterozygous mutations in *ETV6* (TEL) and frequent absence of *ETV6* protein in acute myeloid leukemia. *Oncogene*. 24:4129–4137.
- Bernassola, F., A. Oberst, G. Melino, and P.P. Pandolfi. 2005. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. *Oncogene*. 24:6982–6986. <http://dx.doi.org/10.1038/sj.onc.1208843>
- Bhandoola, A., and A. Sambandam. 2006. From stem cell to T cell: one route or many? *Nat. Rev. Immunol.* 6:117–126. <http://dx.doi.org/10.1038/nri1778>
- Bohlander, S.K. 2005. *ETV6*: a versatile player in leukemogenesis. *Semin. Cancer Biol.* 15:162–174. <http://dx.doi.org/10.1016/j.semcancer.2005.01.008>
- Chiaretti, S., X. Li, R. Gentleman, A. Vitale, M. Vignetti, F. Mandelli, J. Ritz, and R. Foa. 2004. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. *Blood*. 103:2771–2778. <http://dx.doi.org/10.1182/blood-2003-09-3243>
- Chuikov, S., B.P. Levi, M.L. Smith, and S.J. Morrison. 2010. Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. *Nat. Cell Biol.* 12:999–1006. <http://dx.doi.org/10.1038/ncb2101>
- Coustan-Smith, E., C.G. Mullighan, M. Onciu, F.G. Behm, S.C. Raimondi, D. Pei, C. Cheng, X. Su, J.E. Rubnitz, G. Basso, et al. 2009. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. *Lancet Oncol.* 10:147–156. [http://dx.doi.org/10.1016/S1470-2045\(08\)70314-0](http://dx.doi.org/10.1016/S1470-2045(08)70314-0)
- Crum, C.P., and F.D. McKeon. 2010. p63 in epithelial survival, germ cell surveillance, and neoplasia. *Annu. Rev. Pathol.* 5:349–371. <http://dx.doi.org/10.1146/annurev-pathol-121808-102117>
- Du, Y., N.A. Jenkins, and N.G. Copeland. 2005. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. *Blood*. 106:3932–3939. <http://dx.doi.org/10.1182/blood-2005-03-1113>




- Duhoux, F.P., G. Ameye, C.P. Montano-Almendras, K. Bahloul, M.J. Mozziconacci, S. Laibe, I. Wlodarska, L. Michaux, P. Talmant, S. Richebourg, et al; on behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO). 2011. PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. *Br. J. Haematol.* (Epub ahead of print).
- Fenrick, R., L. Wang, J. Nip, J.M. Amann, R.J. Rooney, J. Walker-Daniels, H.C. Crawford, D.L. Hulboy, M.S. Kinch, L.M. Matrisian, and S.W. Hiebert. 2000. TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1. *Mol. Cell. Biol.* 20:5828–5839. <http://dx.doi.org/10.1128/MCB.20.16.5828-5839.2000>
- Ferrando, A.A. 2009. The role of NOTCH1 signaling in T-ALL. *Hematology (Am Soc Hematol Educ Program)*. 1:353–361. <http://dx.doi.org/10.1182/asheducation-2009.1.353>
- Ferrando, A.A., D.S. Neuberg, J. Staunton, M.L. Loh, C. Huard, S.C. Raimondi, F.G. Behm, C.H. Pui, J.R. Downing, D.G. Gilliland, et al. 2002. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. *Cancer Cell*. 1:75–87. [http://dx.doi.org/10.1016/S1535-6108\(02\)00018-1](http://dx.doi.org/10.1016/S1535-6108(02)00018-1)
- Ferrando, A.A., D.S. Neuberg, R.K. Dodge, E. Paietta, R.A. Larson, P.H. Wiernik, J.M. Rowe, M.A. Caligiuri, C.D. Bloomfield, and A.T. Look. 2004. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. *Lancet*. 363:535–536. [http://dx.doi.org/10.1016/S0140-6736\(04\)15542-6](http://dx.doi.org/10.1016/S0140-6736(04)15542-6)
- Golub, T.R., D.K. Slonim, P. Tamayo, C. Huard, M. Gaasenbeek, J.P. Mesirov, H. Coller, M.L. Loh, J.R. Downing, M.A. Caligiuri, et al. 1999. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science*. 286:531–537. <http://dx.doi.org/10.1126/science.286.5439.531>
- Gould, J., G. Getz, S. Monti, M. Reich, and J.P. Mesirov. 2006. Comparative gene marker selection suite. *Bioinformatics*. 22:1924–1925. <http://dx.doi.org/10.1093/bioinformatics/btl196>
- Hock, H., E. Meade, S. Medeiros, J.W. Schindler, P.J. Valk, Y. Fujiwara, and S.H. Orkin. 2004. Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. *Genes Dev.* 18:2336–2341. <http://dx.doi.org/10.1101/gad.1239604>
- Homminga, I., R. Pieters, A.W. Langerak, J.J. de Rooi, A. Stubbs, M. Verstegen, M. Vuerhard, J. Buijs-Gladdines, C. Kooi, P. Klous, et al. 2011. Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. *Cancer Cell*. 19:484–497. <http://dx.doi.org/10.1016/j.ccr.2011.02.008>
- Ley, T.J., L. Ding, M.J. Walter, M.D. McLellan, T. Lamprecht, D.E. Larson, C. Kandoth, J.E. Payton, J. Baty, J. Welch, et al. 2010. DNMT3A mutations in acute myeloid leukemia. *N. Engl. J. Med.* 363:2424–2433. <http://dx.doi.org/10.1056/NEJMoa1005143>
- Marks, D.I., E.M. Paietta, A.V. Moorman, S.M. Richards, G. Buck, G. DeWald, A. Ferrando, A.K. Fielding, A.H. Goldstone, R.P. Ketterling, et al. 2009. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood*. 114:5136–5145. <http://dx.doi.org/10.1182/blood-2009-08-231217>
- Monti, S., P. Tamayo, J.P. Mesirov, and T. Golub. 2003. Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data. *Journal Machine Learning*. 52:91–118. <http://dx.doi.org/10.1023/A:1023949509487>
- Novershtern, N., A. Subramanian, L.N. Lawton, R.H. Mak, W.N. Haining, M.E. McConkey, N. Habib, N. Yosef, C.Y. Chang, T. Shay, et al. 2011. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. *Cell*. 144:296–309. <http://dx.doi.org/10.1016/j.cell.2011.01.004>
- Paganin, M., and A. Ferrando. 2011. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. *Blood Rev.* 25:83–90. <http://dx.doi.org/10.1016/j.blre.2010.09.004>
- Palomero, T., M.L. Sulis, M. Cortina, P.J. Real, K. Barnes, M. Ciofani, E. Caparros, J. Buteau, K. Brown, S.L. Perkins, et al. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. *Nat. Med.* 13:1203–1210. <http://dx.doi.org/10.1038/nm1636>
- Pui, C.H., L.L. Robison, and A.T. Look. 2008. Acute lymphoblastic leukaemia. *Lancet*. 371:1030–1043. [http://dx.doi.org/10.1016/S0140-6736\(08\)60457-2](http://dx.doi.org/10.1016/S0140-6736(08)60457-2)
- Soulier, J., E. Clappier, J.M. Cayuela, A. Regnault, M. García-Peydró, H. Dombret, A. Baruchel, M.L. Toribio, and F. Sigaux. 2005. HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). *Blood*. 106:274–286. <http://dx.doi.org/10.1182/blood-2004-10-3900>
- Strehl, S., K. Nebral, M. König, J. Harbott, H. Strobl, R. Ratei, S. Struski, B. Bielorai, M. Lessard, M. Zimmermann, et al. 2008. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations. *Clin. Cancer Res.* 14:977–983. <http://dx.doi.org/10.1158/1078-0432.CCR-07-4022>
- Su, X., H. Drabkin, E. Clappier, E. Morgado, M. Busson, S. Romana, J. Soulier, R. Berger, O.A. Bernard, and C. Lavau. 2006. Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3. *Genes Chromosomes Cancer*. 45:846–855. <http://dx.doi.org/10.1002/gcc.20348>
- Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA*. 102:15545–15550. <http://dx.doi.org/10.1073/pnas.0506580102>
- Thompson, B.J., S. Buonamici, M.L. Sulis, T. Palomero, T. Vilimas, G. Basso, A. Ferrando, and I. Aifantis. 2007. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. *J. Exp. Med.* 204:1825–1835. <http://dx.doi.org/10.1084/jem.20070872>
- Van Vlierberghe, P., J.P. Meijerink, R.W. Stam, W. van der Smitten, E.R. van Wering, H.B. Beverloo, and R. Pieters. 2005. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. *Blood*. 106:4414–4415. <http://dx.doi.org/10.1182/blood-2005-06-2267>
- Weng, A.P., A.A. Ferrando, W. Lee, J.P. Morris IV, L.B. Silverman, C. Sanchez-Irizarry, S.C. Blacklow, A.T. Look, and J.C. Aster. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science*. 306:269–271. <http://dx.doi.org/10.1126/science.1102160>
- Yilmaz, O.H., R. Valdez, B.K. Theisen, W. Guo, D.O. Ferguson, H. Wu, and S.J. Morrison. 2006. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature*. 441:475–482. <http://dx.doi.org/10.1038/nature04703>
- Zenatti, P.P., D. Ribeiro, W. Li, L. Zuurbier, M.C. Silva, M. Paganin, J. Tritapoe, J.A. Hixon, A.B. Silveira, B.A. Cardoso, et al. 2011. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. *Nat. Genet.* 43:932–939. <http://dx.doi.org/10.1038/ng.924>
- Zhang, J., J.C. Grindley, T. Yin, S. Jayasinghe, X.C. He, J.T. Ross, J.S. Haug, D. Rupp, K.S. Porter-Westpfahl, L.M. Wiedemann, et al. 2006. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. *Nature*. 441:518–522. <http://dx.doi.org/10.1038/nature04747>

## SUPPLEMENTAL MATERIAL


Van Vlierberghe et al., <http://www.jem.org/cgi/content/full/jem.20112239/DC1>

**Figure S1. Independent validation of gene expression cluster in adult T-ALL.** Consensus clustering analysis in a validation series of 30 adult T-ALL samples (top). Crossed GSEA of genes differentially expressed in clusters I and II identified in the discovery and validation series (bottom).



**Figure S2. ETV6 mutant gene signature in early immature adult T-ALL.** Supervised analysis of *ETV6* mutant versus *ETV6* wild-type gene expression signatures in early immature adult T-ALLs ( $P < 0.001$ ;  $FC > 1.25$ ). Genes significantly up-regulated and down-regulated in *ETV6* mutant early immature adult T-ALLs are shown in a heatmap. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.





**Figure S3. LOUCY is a T-ALL cell line with a transcriptional program highly related to early immature adult T-ALL.** GSEA of transcripts significantly up-regulated in early immature adult T-ALL in gene expression signatures obtained from a panel of T-ALL cell lines. Leading edge genes are shown in a heatmap of genes up-regulated in early immature *ETV6* mutant T-ALL that are most differentially expressed in between LOUCY and other T-ALL cell lines, including ALL-SIL, CCRF, CTV1, CUTLL1, DND41, HPB-ALL, KOPITK1, RPMI8402, and T-ALL-1. Genes in the heat map are shown in rows and each individual sample is shown in one column. The scale bar shows color-coded differential expression from the mean in standard deviation units, with red indicating higher levels and blue lower levels of expression.

**Table S1.** Adult T-ALL immunophenotypes ( $n = 57$ )

	ID	TdT	CD133	CD117	CD34	cCD3	CD5	mfi_CD5	CD1	CD7	CD2	CD3	TCR AB	TCR GD	CD4	CD8	CD33	CD13	CD11b
Cluster I	1	99	nt	0	99	99	0	1.1	0	99	99	0	0	0	0	0	99	99	99
Cluster I	2	99	0	0	99	96	99	51.5	0	99	99	99weak	0	0	0	0	0	99	0
Cluster I	3	14	30	0	99	99	99	11.0	0	99	0	0	0	0	0	0	99	0	99
Cluster I	4	99	0	0	0	99	99	25.4	99	99	99	0	1	0	99	99	0	0	0
Cluster I	5	99	0	98	99	99	99	4.0	0	99	0	0	0	0	0	0	99	0	99
Cluster I	6	99	99	99	99	99	0	1.1	0	99	99	0	0	0	0	0	0	99weak	99
Cluster I	7	99	0	0	0	99	99	22.6	99	99	99weak	0	0	0	99	99	0	0	0
Cluster I	8	99	95	99	99	99	99	9.3	0	99	0	0	0	0	0	0	95	95	99
Cluster I	9	7	0	99	0	97	0	5.9	0	99	0	99	0	0	0	0	0	99	0
Cluster I	10	99	0	0	55	97	0	1.0	0	99	0	0	0	0	0	0	99	0?	0
Cluster I	11	90	0	99	0	99	93	16.4	nt	99	0	0	0	0	0	0	0	99	0
Cluster I	12	97	99	0	99	99	99	4.1	0	99	99weak	0	0	0	0	0	99	99	99
Cluster I	13	nt	0	20	99	99	50	4.2	0	99	99weak	0	0	0	0	0	99weak	99weak	40
Cluster I	14	28	98	99	99	99	93	18.6	0	99	90	0	0	0	0	99	0	0	0
Cluster I	15	91	nt	99	99	99	0	1.9	0	98	99	0	0	0	0	0	99weak	99	95
Cluster I	16	94	99	99	99	99	0	1.1	0	99	44	0	0	0	0	0	0	99	98
Cluster I	17	99	0	0	0	99	99	18.2	0	99	0	0	0	0	0	0	0	99	0
Cluster I	18	30	95	0	99	99	99	10.7	0	99	0	99	0	0	0	0	99	99weak	99
Cluster I	19	99	97	99	98	99	0	1.2	0	99	99	0	0	0	0	0	0	98	20
Cluster I	20	15	99	40	20	99	0	1.7	0	99	0	0	0	0	0	0	99	0	90
Cluster I	21	99	99	0	99	99	95	6.7	0	99	99weak	0	0	0	29	0	99	95	90
Cluster I	22	20	0	95	99	99	99	4.1	0	98	0	0	0	0	0	95	96	95	0
Cluster I	23	20	95	0	99	99	99	11.1	0	99	0	0	0	0	0	0	99	99	0
Cluster I	24	99	90	56	99	99	99	13.1	0	99	99weak	0	0	0	0	0	99	99weak	99
Cluster I	25	99	0	99	0	99	0	1.7	0	99	0	99	0	0	0	99	0	99	0
Cluster I	26	nt	nt	0	99	99	99	13.4	nt	99	99	0	nt	nt	nt	nt	0	nt	0
Cluster I	27	99	99	0	99	99	99	12.7	0	99	0	0	0	0	0	0	99	99	99
Cluster I	28	0	0	0	0	99	0	1.1	0	99	0	0	0	0	99	0	0	0	0
Cluster I	29	0	99	20	99	99	99	4.3	0	99	0	0	99	0	0	0	99	0	99
	ID	TdT	CD133	CD117	CD34	cCD3	CD5	mfi_CD5	CD1	CD7	CD2	CD3	TCR AB	TCR GD	CD4	CD8	CD33	CD13	CD11b
Cluster II	30	38	0	0	0	94	96	60.5	91	97	98	0	nt	nt	95	98	0	0	0
Cluster II	31	60	nt	0	99	99	99	26.1	30	99	99	99	99	0	0	90	0	0	0
Cluster II	32	99	nt	0	0	81	96	1.9	45	97	92	95	3	0	77	90	42	0	15
Cluster II	33	89	0	0	0	99	99	28.5	99	99	99	99	0	0	99	99	0	0	0
Cluster II	34	98	0	0	99	99	99	4.2	0	99	40	0	0	0	0	99	0	99	0
Cluster II	35	99	0	0	20	99	99	29.3	0	99	99	99	0	0	99	99	99	0	0
Cluster II	36	96	0	0	0	99	99	48.8	99	99	99	0	0	0	99	99	0	0	0
Cluster II	37	99	0	0	0	99	99	32.1	99	99	99	0	0	0	99	99	0	0	0
Cluster II	38	99	0	0	0	99	99	17.6	99	99	0	55	99	0	0	0	99	99	0
Cluster II	39	99	0	0	0	99	99	6.7	0	99	0	0	0	0	99	99	0	0	0
Cluster II	40	99	99	0	99	99	99	30.4	0	99	30	0	0	0	0	99	0	99	99
Cluster II	41	99	0	0	99	99	99	16.5	0	99	70	99	0	99	0	75	0	99	0
Cluster II	42	99	0	0	30	99	99	29.5	99	99	99	0	0	0	95	60	0	30	0
Cluster II	43	99	0	0	nt	99	99	21.9	35	99	76	99	0	99	99	99	0	0	0
Cluster II	44	99	0	0	99	99	99	17.8	0	99	99	99	0	0	0	0	0	99	0
Cluster II	45	99	nt	nt	nt	99	99	23	99	99	99	0	0	0	99	99	0	0	0
Cluster II	46	99	0	0	0	99	99	28.6	99	99	99	40	0	0	99	99	0	99	0
Cluster II	47	92	0	0	99	99	99	8.5	0	99	99	99	0	0	99	99	0	99	0
Cluster II	48	99	0	0	0	99	99	18.0	99	98	99	0	0	0	99	99	0	0	0
Cluster II	49	96	0	0	99	97	95	5.1	0	94	94	0	0	0	99	99	0	0	0
Cluster II	50	99	0	0	99	99	99	8.9	0	99	99	0	0	0	0	99	0	98	99
Cluster II	51	99	0	0	99	99	95	32.7	0	99	99	0	0	0	0	99	0	99	0

**Table S1.** Adult T-ALL immunophenotypes ( $n = 57$ ) (*Continued*)

	ID	TdT	CD133	CD117	CD34	cCD3	CD5	mfi_CD5	CD1	CD7	CD2	CD3	TCR AB	TCR GD	CD4	CD8	CD33	CD13	CD11b
Cluster II	52	0	0	0	0	99	0	1.1	0	99	50	0	0	0	0	0	0	99	0
Cluster II	53	58	0	0	0	99	99	5.7	95	99	99	99	0	0	99	99	0	0	0
Cluster II	54	99	0	0	0	99	99	17.8	0	99	0	45	0	0	0	0	0	90	0
Cluster II	55	99	0	99	0	99	99	15.2	95	99	99	0	0	0	95	95	0	0	0
Cluster II	56	0	0	0	0	99	99	15.6	0	99	99	99	0	0	0	99	0	0	0
Cluster II	57	nt	nt	0	0	99	99	31.3	nt	99	99	0	nt	nt	nt	nt	0	nt	0



**Table S2.** Myeloid and T-lymphoid specific genetic alterations in adult T-ALL ( $n = 57$ ).

	Myeloid mutations					T-ALL mutations			
	ID	IDH1	IDH2	FLT3	NRAS	DNMT3A	NOTCH1	FBXW7	IL7R
Immature/Cluster I	1	0	0	0	1	0	0	0	0
Immature/Cluster I	2	0	0	0	0	0	0	0	0
Immature/Cluster I	3	0	0	0	1	0	1	0	0
Immature/Cluster I	4	0	0	0	0	0	0	0	0
Immature/Cluster I	5	0	0	0	0	0	1	0	0
Immature/Cluster I	6	0	0	1	0	0	0	0	0
Immature/Cluster I	7	0	0	0	0	0	0	0	0
Immature/Cluster I	8	1	0	0	0	0	0	0	0
Immature/Cluster I	9	0	1	0	0	0	0	1	0
Immature/Cluster I	10	0	0	0	0	0	1	0	1
Immature/Cluster I	11	0	0	0	0	0	0	0	0
Immature/Cluster I	12	0	1	0	0	1	1	0	0
Immature/Cluster I	13	0	1	0	1	0	1	0	0
Immature/Cluster I	14	0	0	0	0	0	0	0	0
Immature/Cluster I	15	0	0	1	0	0	0	0	0
Immature/Cluster I	16	0	0	1	0	0	0	0	0
Immature/Cluster I	17	0	0	0	0	0	0	0	0
Immature/Cluster I	18	0	0	0	0	0	1	0	0
Immature/Cluster I	19	0	0	0	0	0	0	0	0
Immature/Cluster I	20	0	0	0	1	0	0	0	0
Immature/Cluster I	21	0	0	0	0	0	0	0	0
Immature/Cluster I	22	0	0	1	0	0	1	0	0
Immature/Cluster I	23	0	0	0	0	0	0	0	0
Immature/Cluster I	24	0	0	0	0	0	1	0	0
Immature/Cluster I	25	0	0	0	0	1	1	0	0
Immature/Cluster I	26	0	0	0	0	0	1	0	0
Immature/Cluster I	27	0	0	0	1	0	1	0	0
Immature/Cluster I	28	0	0	0	0	0	0	0	0
Immature/Cluster I	29	0	0	1	0	0	0	0	0
non-immature Cluster II	30	0	0	0	0	0	1	0	0
non-immature Cluster II	31	0	0	0	0	0	0	0	0
non-immature Cluster II	32	0	0	0	0	0	1	0	0
non-immature Cluster II	33	0	0	0	0	0	1	1	0
non-immature Cluster II	34	0	0	0	0	0	0	0	0
non-immature Cluster II	35	0	0	0	0	0	1	0	1
non-immature Cluster II	36	0	0	0	1	0	0	1	0
non-immature Cluster II	37	0	0	0	0	0	1	0	0
non-immature Cluster II	38	0	0	0	0	0	1	0	1
non-immature Cluster II	39	0	0	0	0	0	1	0	1
non-immature Cluster II	40	0	0	0	0	0	1	0	0
non-immature Cluster II	41	0	0	0	0	0	1	0	0
non-immature Cluster II	42	0	0	0	0	0	1	0	1
non-immature Cluster II	43	0	0	0	0	0	0	1	1
non-immature Cluster II	44	0	0	0	0	0	1	0	0
non-immature Cluster II	45	0	0	0	0	0	1	0	0
non-immature Cluster II	46	0	0	0	0	0	1	0	0
non-immature Cluster II	47	0	0	0	0	0	1	1	0
non-immature Cluster II	48	0	0	0	0	0	1	0	0
non-immature Cluster II	49	0	0	0	0	0	1	1	0
non-immature Cluster II	50	0	0	0	0	0	1	0	0
non-immature Cluster II	51	0	0	0	0	0	1	0	0

**Table S2.** Myeloid and T-lymphoid specific genetic alterations in adult T-ALL ( $n = 57$ ). (Continued)

	Myeloid mutations					T-ALL mutations			
	ID	IDH1	IDH2	FLT3	NRAS	DNMT3A	NOTCH1	FBXW7	IL7R
non-immature Cluster II	52	0	0	0	0	0	0	0	0
non-immature Cluster II	53	0	0	0	0	0	1	0	1
non-immature Cluster II	54	0	0	0	0	0	1	0	0
non-immature Cluster II	55	0	0	0	0	0	1	0	0
non-immature Cluster II	56	0	0	0	0	0	0	0	0
non-immature Cluster II	57	0	0	0	0	0	0	0	0

**Table S3.** ETV6 mutant adult T-ALL immunophenotypes ( $n = 10$ )

ID	TdT	CD117	CD34	CD13	CD33	CD10	CD11b	cCD3	CD5	CD1	CD7	CD2	CD3	TCR AB	TCR GD	CD4	CD8
3	14	0	99	0	99	0	99	99	99weak	0	99	0	0	0	0	0	0
5	99	98	99	0	99	0	99	99	99weak	0	99	0	0	0	0	0	0
18	30	0	99	99weak	99	0	99	99	99	0	99	0	99	0	0	0	0
24	99	56	99	99weak	99	0	99	99	99	0	99	99weak	0	0	0	0	0
27	NA	0	99	99	99	0	99	99	99weak	0	99	0	0	0	0	0	0
58	99	0	36	0	99	0	62	99	99	0	92	25	0	NA	NA	0	0
59	21	0	96	92	91	60	95	90	87	0	92	96	0	NA	NA	0	0
60	99	0	99	99	99	99	99	99	99	0	99	99	0	0	0	0	0
61	89	0	99	99	99	84	98	99	0	0	99	0	0	0	0	0	0
62	99	0	80	99	99	99	99	99	99	0	99	99	0	0	0	0	0

**Table S4.** ETV6 PCR and sequencing primers.

Primer Sequence		
Exon 1	Forward	5'-GGGGAGAGATGCTGGAAGAAA-3'
Exon 1	Reverse	5'-TTTCATTGTCAAAAAGCAAGG-3'
Exon 2	Forward	5'-CCGAGATGGTCTCATACCTCC-3'
Exon 2	Reverse	5'-TGAGAAACAAGGAACAGGAACC-3'
Exon 3	Forward	5'-GACCTTCTCCCTTTATTCCAGC-3'
Exon 3	Reverse	5'-TCCTTCAACTCCTTCCATCG-3'
Exon 4	Forward	5'-TGCGCTCCAATTGTATCTTTG-3'
Exon 4	Reverse	5'-TGAGCTTCAGGGAACCAAGAG-3'
Exon 5	Forward	5'-TCCTCCATTACCGCTGTAG-3'
Exon 5	Reverse	5'-CTAATTGGGAATGGTGCAG-3'
Exon 6	Forward	5'-CAAGCTAGGCAGAAGCAGTTG-3'
Exon 6	Reverse	5'-ACGATTATCCTCCAATCCAGG-3'
Exon 7	Forward	5'-TAATAGCTCCCGCAGTGCC-3'
Exon 7	Reverse	5'-TGTAGCAATGATTGGCTTTGG-3'
Exon 8	Forward	5'-GGGTTCAAGTAGCTCTCCAGC-3'
Exon 8	Reverse	5'-TCTGCAAGAGAAGTGTCCTG-3'